Format

Send to

Choose Destination
See comment in PubMed Commons below
Chin Clin Oncol. 2013 Dec;2(4):36. doi: 10.3978/j.issn.2304-3865.2013.07.04.

Percutaneous therapies of hepatocellular carcinoma-an update.

Author information

1
The Russell H. Morgan Department of Radiology and Radiological Sciences, Section of Interventional Radiology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
2
The Russell H. Morgan Department of Radiology and Radiological Sciences, Section of Interventional Radiology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. jfg@jhmi.edu.

Abstract

Percutaneous image-guided tumor therapies have proved important in the treatment of patients with primary liver cancer. The therapeutic spectrum for the management of this patient group includes ablative techniques such as ethanol ablation and radiofrequency ablation for patients with early-stage disease as well as intra-arterial approaches such as radioembolization and transarterial chemoembolization for patients with intermediate and end-stage disease. The tremendous advantage of such therapies is the reduced systemic toxicity combined with efficient local tumor control. However, specific therapeutic algorithms continue to be highly unstandardized and depend on individual experience of the operator. In this review, we will describe the rationale behind several percutaneous techniques, focusing on intra-arterial therapies of hepatocellular carcinoma (HCC) and review the available clinical evidence. We will also discuss new developments such as the combination of intra-arterial therapies with new systemically applicable drugs.

KEYWORDS:

Hepatocellular carcinoma (HCC); deb-tace; intraarterial therapy; radioembolization; sorafenib

Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for AME Publishing Company
    Loading ...
    Support Center